Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
3 hedge funds and large institutions have $1.1M invested in Global X China Biotech Innovation ETF in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
35% more capital invested
Capital invested by funds: $820K → $1.1M (+$285K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$289K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$154K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $602K | +$289K | +15,851 | +98% |
|
|
2
Jane Street
New York
| $486K | -$154K | -8,423 | -25% |
|
|
3
UBS Group
Zurich,
Switzerland
| $17K | +$16K | +879 | New |
|
CHB Hedge Fund Activity: Q2 2021 in Review
3 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q2 2021, worth a combined $1.1M — up 35% from $820K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CHB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $289K. The largest seller was Jane Street, cutting an estimated $154K.
- 3 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q2 2021, up from 2 in Q1 2021.
- Funds reported $1.1M of Global X China Biotech Innovation ETF stock for Q2 2021, up 35% quarter-over-quarter.
- 1 fund opened new Global X China Biotech Innovation ETF positions in Q2 2021 and 0 closed out, a net change of +1 holder.
- The largest Global X China Biotech Innovation ETF buyer in Q2 2021 was Susquehanna International Group, an estimated $289K added.
- The largest Global X China Biotech Innovation ETF seller in Q2 2021 was Jane Street, an estimated $154K sold.
Based on aggregated 13F filings for Q2 2021.